Introduction to Therapy Selection In Brca Mutated Ovarian Cancer
Let's dive into the details surrounding Therapy Selection In Brca Mutated Ovarian Cancer. Bradley J. Monk, MD, FACS, FACOG; Matthew Powell, MD; David O'Malley, MD; Ursula Matulonis, MD; and Shannon N. Westin, ...
Therapy Selection In Brca Mutated Ovarian Cancer Comprehensive Overview
An overview of the SOLO-1 clinical trial in Bradley J. Monk, MD, FACOG, FACS, describes the case of a 40-year-old Caucasian female patient diagnosed with ... Treatment selection
Bradley J. Monk, MD, FACOG, FACS, reacts to advances in molecular testing used to identify predictive biomarkers to guide ...
Summary & Highlights for Therapy Selection In Brca Mutated Ovarian Cancer
- Kathleen N. Moore, MD, assistant professor, The Stephenson
- David O'Malley, MD, professor in the Department of Obstetrics and Gynecology at The Ohio State University College of Medicine, ...
- Considerations for monitoring and managing patients with newly diagnosed
- In this November 5, 2019 webinar, the Basser Center's Director of Gynecologic
- Expert oncologists consider the use of olaparib and bevacizumab as maintenance
That wraps up our extensive overview of Therapy Selection In Brca Mutated Ovarian Cancer.